Table 1.
Study population in the A proliferation inducing ligand (APRIL) cohort.
| Parameter | |
|---|---|
| Number | 31 |
| Sex (male/female) | 18/13 (58.1/41.9%) |
| Age median (range) (years) | 59 (26–83) |
| Staging | |
| T1–T2–T3–T4 | 0–0–14–3 (0–0–45.2–9.7%) |
| N0–N1 | 5–11 (16.1–35.5%) |
| M0–M1 | 16–12 (51.6–38.7%) |
| G2–G3 | 11–7 (35.5–22.6%) |
| R0–R1–R2 | 9–3–1 (29.0–9.7–3.2%) |
| UICC | |
| I–II–III–IV | 0–17–1–12 (0–54.8–3.2–38.7%) |
| ECOG | |
| ECOG 0 | 11 (35.5%) |
| ECOG I | 17 (54.8%) |
| ECOG II | 3 (9.7%) |
| ECOG III | 0 (0%) |
| ECOG IV | 0 (0%) |
| Fatigue | |
| None | 10 (32.2%) |
| Low | 1 (3.2%) |
| Medium | 9 (29.0%) |
| High | 11 (35.5%) |
| Pain scale | |
| 0 | 13 (41.9%) |
| 1–4 | 7 (22.6%) |
| 5–7 | 9 (29.0%) |
| 8–10 | 2 (6.5%) |
| CRP median (range) (mg/L) | 8.0 (0.00–134.00) |
| Bilirubin median (range) (mg/L) | 0.60 (0.20–26.20) |
| GGT median (range) (U/L) | 218 (21–2138) |
| AP median (range) (U/L) | 167 (64–1574) |
| AST median (range) (U/L) | 28 (17–202) |
| ALT median (range) (U/L) | 35 (15–451) |
| CEA median (range) (µg/L) | 3.5 (1.2–16.0) |
| CA 19-9 median (range) (kU/L) | 46 (2–10,000) |
| Creatinine median (range) (mg/dL) | 0.8 (0.5–3.3) |
| WBC median (range) (cells/µg) | 7.4 (5.4–10.5) |